Sait Ashina
Beth Israel Deaconess Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sait Ashina as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:25 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT04693533 · Fremanezumab, Migraine and SleepBeth Israel Deaconess Medical Center · terminated · Migraine Disorders, Sleep Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:25 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Generalized hyperalgesia in patients with chronic tension-type headache.Cephalalgia · 2006137 citationsRCR 5.3
- The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.J Headache Pain · 202092 citationsRCR 7.0
- 43 citationsRCR 1.4
- Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial.Cephalalgia · 202238 citationsRCR 4.4
- 35 citationsRCR 5.5
- Combination of low-dose mirtazapine and ibuprofen for prophylaxis of chronic tension-type headache.Eur J Neurol · 200731 citationsRCR 1.2
- Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial.Neurology · 202425 citationsRCR 4.8
- Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine.Cephalalgia · 20257 citationsRCR 2.5